Mycophenolate mofetil embryopathy

Mycophenolate mofetil embryopathy (also known as mycophenolate embryopathy or MMF embryopathy) is a rare pattern of congenital malformations that occurs in infants exposed to mycophenolate mofetil (MMF) or mycophenolic acid (MPA) during pregnancy. Mycophenolate mofetil is an immunosuppressive medication commonly used to prevent organ transplant rejection and to treat autoimmune conditions such as lupus. When taken during pregnancy, particularly during the first trimester, it acts as a teratogen and can cause a recognizable pattern of birth defects. The condition primarily affects the craniofacial structures, ears, limbs, heart, kidneys, and other organ systems. Key clinical features include microtia (underdeveloped ears) and aural atresia (absence or closure of the ear canal), cleft lip and/or cleft palate, micrognathia (small jaw), hypertelorism (widely spaced eyes), and external ear anomalies. Congenital heart defects, including septal defects, are frequently reported. Limb anomalies such as brachydactyly (short fingers) and hypoplastic or absent nails may also occur. Additional features can include esophageal atresia, diaphragmatic hernia, renal malformations, and eye abnormalities including coloboma. Exposure to mycophenolate during pregnancy also carries a significant risk of first-trimester miscarriage, estimated at 45-49%. There is no specific treatment for mycophenolate mofetil embryopathy itself; management is supportive and directed at the individual malformations present. Surgical correction may be required for cleft lip/palate, congenital heart defects, or other structural anomalies. Hearing aids or surgical interventions may be needed for ear-related hearing loss. Prevention is the most critical strategy: women of childbearing potential taking mycophenolate should use effective contraception, and the medication should be discontinued and replaced with a pregnancy-safe alternative at least six weeks before conception. Genetic counseling is recommended for affected families.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Mycophenolate mofetil embryopathy